Rilmazafone is a prescription medication used in Japan to treat insomnia. It is a prodrug, meaning the body converts it into active benzodiazepines with sedative and hypnotic effects, including rilmazolam. Its clinical uses include its sedative and soporific properties, though long-term use can lead to drug dependence and it has been linked to fatalities in cases of misuse or contamination in other countries. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Rilmazafona and Rilmazafonum. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 5069.
Rilmazafone
| CAS No | 99593-25-6 |
|---|---|
| Molecular Formula | C21H20Cl2N6O3 |
| Molecular Weight | 475.3 g/mol |
| Synonyms | 5-[[(2-aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rilmazafone is a prescription medication used in Japan to treat insomnia. It is a prodrug, meaning the body converts it into active benzodiazepines with sedative and hypnotic effects, including rilmazolam.
The listed CAS number is 99593-25-6.
The listed molecular formula is C21H20Cl2N6O3.
The listed molecular weight is 475.3 g/mol.
5-[[(2-aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide.
The source lists Rilmazafona and Rilmazafonum.